XCSFDHG46767FHJHJF
tdp2664 InvestorPlace In a late October article, we suggested that the Abbott Laboratories (NYSE: ABT ) spin-off of its proprietary pharmaceutical business into a separate company may be the beginning of a trend. It appears that just may be the case. Dublin, Ireland-based Covidien (NYSE: COV ) said today it's going to follow in Abbott's footsteps and separate its pharma business into a publicly traded firm. President and CEO José Almeida said the company has been considering this move for years, according to FiercePharma . Earlier, it had been reported that Covidien had hired JPMorgan to find a buyer that might be willing to pay $4 billion for the business. Almeida didn't indicate whether the company found any takers, but
No comments:
Post a Comment